← back to search

Masoud Vedadi

Ontario Institute for Cancer Research ·
Area of research
Molecular Biology
Research interest
Research interests include Cancer-related gene regulation, Epigenetics and DNA Methylation, Ubiquitin and proteasome pathways, and RNA modifications and cancer.
h-index
71
citations
18,668
works
401
NIH funding
primary concept
email

Recent publications

Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor
Journal of Medicinal Chemistry 2024cited by 3position: middledoi
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase
Journal of Medicinal Chemistry 2023cited by 47position: middledoi
CACHE (Critical Assessment of Computational Hit-finding Experiments): A public–private partnership benchmarking initiative to enable the development of computational methods for hit-finding
Nature Reviews Chemistry 2022cited by 99position: middledoi
Crystal structure of <scp>SARS‐CoV</scp>‐2 nsp10–nsp16 in complex with small molecule inhibitors, <scp>SS148</scp> and <scp>WZ16</scp>
Protein Science 2022cited by 44position: lastdoi
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors
SLAS DISCOVERY 2021cited by 89position: lastdoi
Target 2035 – update on the quest for a probe for every protein
RSC Medicinal Chemistry 2021cited by 79position: middledoi
A chemical toolbox for the study of bromodomains and epigenetic signaling
Nature Communications 2019cited by 124position: middledoi
A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion
eLife 2019cited by 60position: middledoi
Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1)
Journal of Medicinal Chemistry 2019cited by 34position: middledoi
A chemical biology toolbox to study protein methyltransferases and epigenetic signaling
Nature Communications 2018cited by 149position: middledoi
A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases
ACS Chemical Biology 2015cited by 290position: middledoi
WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma
Cancer Research 2015cited by 123position: middledoi
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Clinical Epigenetics 2015cited by 81position: middledoi
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
Blood 2014cited by 230position: middledoi
A Strategy for Modulation of Enzymes in the Ubiquitin System
Science 2013cited by 296position: middledoi
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Nature Communications 2012cited by 286position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Fengling Li · Weifang Medical University10 papers (2014–2024)Jian Jin · Zhengzhou Central Hospital8 papers (2014–2024)C.H. Arrowsmith · University Health Network5 papers (2015–2024) · 5 papers (2019–2024)Jing Liu · Peking University5 papers (2015–2024)H. Ümit Kanıskan · Mount Sinai Medical Center4 papers (2015–2023)Matthieu Schapira · University Health Network3 papers (2015–2021)Paul E. Brennan · University of Birmingham3 papers (2019–2024)Peter J. Brown · Columbia University3 papers (2015–2021)Minkui Luo · Memorial Sloan Kettering Cancer Center3 papers (2018–2022)Dalia Baršytė-Lovejoy · University of Toronto3 papers (2015–2019) · 2 papers (2019–2024)Yan Xiong · Jiujiang University2 papers (2019–2024) · 2 papers (2021–2023) · 2 papers (2019–2019) · 2 papers (2021–2022) · 2 papers (2019–2024) · 2 papers (2019–2024)Deyao Li · Peking University2 papers (2021–2022)Kwang‐Su Park · Keimyung University2 papers (2019–2024)